| Oct 31 |
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
|
| Oct 31 |
Lexicon's sotagliflozin fails to win support of FDA AdComm for diabetes (update)
|
| Oct 27 |
FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
|
| Oct 23 |
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024
|
| Oct 22 |
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
|
| Oct 17 |
Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe
|
| Oct 17 |
Lexicon partners Viatris for global expansion of sotagliflozin
|
| Oct 16 |
Viatris to market Lexicon's sotagliflozin outside of US, Europe
|
| Oct 16 |
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
|
| Oct 16 |
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
|
